Highlights

  • Amaero (ASX:3DA) rose 16% to AUD 0.215 but remains down about 46% over one year.
  • No fresh price-sensitive update within the past two days was identified as the direct cause.
  • Q4 FY26 Revenue reached about AUD 9.1mn, up more than fourfold year on year.
  • Trailing 12-month revenue reached about AUD 18.1mn as powder and PM-HIP production scaled.

Amaero Inc (ASX:3DA) gained 16.22% to AUD 0.215, but the stock remains about 46% lower over one year. Turnover reached around AUD 498,000 and the company was valued near AUD 205mn. No fresh price-sensitive announcement within the past two days was identified as the direct trigger. The more important background is the acceleration in commercial revenue from Amaero's US Manufacturing platform, even as the share price continues to reflect concerns around valuation, execution and the pace of scale-up.

Revenue has reached a new level

Amaero reported record Q4 FY26 revenue of around AUD 9.1mn, representing more than 400% year-on-year growth. Trailing 12-month revenue reached approximately AUD 18.1mn, supported by titanium powder, refractory powder and PM-HIP component shipments.

Manufacturing capacity has expanded

The company has completed its initial multi-year Capital Investment program and now operates three EIGA premium atomisers. That gives Amaero substantial domestic capacity for titanium and refractory alloy powders, with additional equipment expansion planned.

Commercial contracts are becoming more visible

During the June quarter, Amaero secured a master purchasing agreement with a minimum commitment of AUD 7.8mn for FY27 titanium alloy powder deliveries. It also has distribution and qualification programs across defence, aerospace, space and medical customers.

The bull case

US policy is strongly supportive of domestic advanced manufacturing and critical-material Supply chains. If Amaero converts qualification programs into recurring production contracts, revenue can scale quickly against a largely installed manufacturing base.

The risks

The one-year share-price decline shows that the market remains cautious despite revenue growth. Manufacturing scale-up can create working-capital pressure, customer qualification can be slow, and government-related contracts can be affected by funding timing. The company still needs to demonstrate sustainable positive EBITDA.

What to watch next

FY27 contracted revenue, utilisation of the three atomisers, gross margin, customer concentration and progress toward positive EBITDA are the key measures.